Zevalin Articles
Spectrum Pharma to acquire non-US rights to market Zevalin
26 January 2012
Spectrum upbeat on lymphoma drug Zevalin study
24 January 2012
Spectrum Pharma licenses lymphoma drug belinostat from TopoTarget for up to $350 million
3 February 2010
Cell Thera gets next $6.5M from Spectrum
9 April 2009
Spectrum's 2008 loss halves to $15.5M
3 April 2009
Cell Thera sells Zevalin to partner Spectrum
2 March 2009
Spectrum and Cell Thera close deal for JV to market Zevalin
22 December 2008
Spectrum and Cell Therapeutics form JV for projected expansion in US sales of Zevalin
8 December 2008
Cell's Zevalin improves PFS in NHL patients
27 October 2008
Cell Thera submits sBLA for Zevalin as first-line therapy
6 October 2008
Cell Therapeutics recruits Craig Philips as president
18 August 2008
EC extends label for Bayer HealthCare
5 May 2008
Cell Thera licenses $65M stock to investor
5 May 2008
CHMP recommends expanded label for Zevalin
31 March 2008
Zevalin follow-up results in 96% remission in NHL
24 March 2008
Zevalin boosts PFS in follicular lymphoma
17 December 2007
Medicare reimbursement change criticized
17 December 2007
Cell Therapeutics buys Zevalin from Biogen Idec for $10M, with up to $20M extra plus milestones
3 September 2007
Zevalin in aggressive Lymphoma trial
16 October 2006
Israeli basket update c'tee recommends another 16 new technologies
4 September 2006
Biogen Idec sees 8% 4th-qtr 2005 sales rise
27 February 2006
Positive Ph II data for Schering AG's Zevalin
20 June 2005
Positive Ph II data for Schering AG's Zevalin
20 June 2005
Biogen Idec boosted by Avonex
14 February 2005
GSK acquires full rights for Bexxar from Corixa
20 December 2004
Stock Commentary - New York
20 December 2004
Biogen Idec's 1st-qtr revenues rise 24%
10 May 2004
Merger costs Biogen Idec a $991M loss
8 March 2004
Schering AG's Zevalin cleared by EC
26 January 2004
IDEC wins patent ruling against Corixa, GSK and Coulter
27 October 2003
Schering AG's Zevalin gets positive opinion
6 October 2003
GSK wins protection for Ceftin antibiotic
12 May 2003
2002's crop of new product launches backs up R&D fears
10 February 2003
IDEC EPS out-performs in fourth qtr
27 January 2003
IDEC 2nd-qtr sales increase 43%
22 July 2002
IDEC forecasts 2nd-qtr EPS at $0.20
15 July 2002
EU launch of NHL drug Zevalin delayed
8 July 2002
Stock Commentary - New York
10 June 2002
IDEC results driven by Rituxan
29 April 2002
March - the turning point for biotech?
15 April 2002
IDEC launches Zevalin in USA for NHL
1 April 2002
Stock Commentary - New York
4 March 2002
Stock Commentary - New York
25 February 2002
Net income up 24% at Schering AG as Betaferon sales stay strong
11 February 2002
Corixa says no Bexxar advisory in February.
21 January 2002
IDEC's Zevalin delayed by FDA request
14 January 2002
IDEC files lawsuits to defend Zevalin
13 September 2001
IDEC's Zevalin set for US approval for NHL
12 September 2001
FDA's ODAC to review Gliadel, Zevalin
4 September 2001
Analyst initiates coverage of PDL and IDEC
31 August 2001
FDA committee to review IDEC's Zevalin
23 July 2001
IDEC files FDA-requested data on Zevalin
12 July 2001
Stock Commentary - New York
7 June 2001
FDA asks for more data on Zevalin
11 May 2001
IDEC Pharma sees Rituxan sales leap 115% in 1st qtr 2001
24 April 2001
Stock Commentary - New York
29 March 2001
Schering AG to "grow faster than market"
16 March 2001
Rituxan combination ups survival in NHL; Zevalin update
6 December 2000
IDEC files for Zevalin OK in USA
3 November 2000
SB, Coulter refile US Bexxar application
19 September 2000
Coulter on verge of refiling Bexxar NDA
7 August 2000
IDEC grows pipeline with immunotherapies
18 April 2000
Stock Commentary New York
10 February 2000
Genentech and IDEC seek to broaden NHL indications for Rituxan
8 December 1999
Coulter and SB suffer on Bexxar resubmission
31 August 1999
Stock Commentary New York
12 August 1999
Idec to hand Rituxan manufacturing to Genentech
24 June 1999
Coulter to file for Bexxar approval soon
24 June 1999
IDEC in $47.5 million deal with Schering AG
11 June 1999
Showing 1-77 of 77 articles
- 1
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
